MALIGNANT MELANOMA IN DOGS

INTRODUCTION
Melanomas are tumors arising from pigment cells. In dogs, they most commonly occur on the skin, in the mouth, and on the toenails. While the majority of skin melanomas are benign in dogs, the majority of oral and toenail melanomas are malignant, with the potential both to invade local tissue, to regrow after surgery, and to spread to other parts of the body. In humans, melanoma development appears to be related to sun exposure. We do not know what causes melanomas to occur in dogs, but sun does not appear to be a factor.

DIAGNOSIS AND STAGING
Most melanomas in the mouth or skin will present as dark, raised masses. In the mouth, they can be associated with drooling, foul odor, bleeding from the mouth, or difficulty eating. Those occurring on the toenail can be associated with toe swelling, loosening of the affected toenail, or lameness on the affected leg. A diagnosis of melanoma will usually require a fine needle aspirate or biopsy. Some melanomas can be misleading because, although derived from pigment cells, they can be a normal, pinkish skin color (so-called amelanotic melanomas).

Prior to devising a treatment plan, some initial tests will usually be performed to determine overall patient health, and if the tumor is localized to the primary site or whether there is any evidence of spread. These tests include blood tests evaluating blood cell number and organ function, a fine needle aspirate of the lymph node draining the tumor area, and X-rays of the lungs and/or tumor site.

TREATMENT AND PROGNOSIS
Surgery is the first line of defense for melanomas. Dogs who receive an aggressive surgery first (to minimize the likelihood of leaving microscopic tumor cells behind) may do better than those receiving conservative surgery. The majority of dogs with malignant melanoma arising from a location other than the skin will develop problems related to tumor recurrence or spread (metastasis) in the future. The average survival time with surgery alone in approximately 6-8 months, with dogs with larger tumors or tumors that have spread to the lymph node more likely to fall short of this mark.

In cases where surgery is not possible or has been declined, another form of local therapy, radiation therapy can sometimes be used. This involves the local application of a powerful form of radiation directly onto the tumor area. Radiation therapy has the potential to shrink many large melanomas, and may be able to delay or prevent local tumor regrowth if tumor cells have been left behind after surgery. The radiation therapy protocol commonly used at CSU for melanomas consists of six weekly treatments, which can be administered on an outpatient basis. The total cost for all 6 treatments is $1,200-1,500.
There have been no controlled studies evaluating the effectiveness of any forms of treatment after surgery to prevent metastasis. There is some indirect evidence that the chemotherapy drug carboplatin might have the ability to delay or prevent metastasis after surgery. This drug is given once every 3 weeks for a total of four treatments. Chemotherapy is generally very well tolerated, with some dogs experiencing mild side effects that usually go away by themselves. Less than 5% of dogs experience severe side effects that would require hospitalization and supportive care. Should unpleasant side effects be noted, future doses of chemotherapy are reduced to decrease the likelihood of additional side effects occurring (See the handout CHEMOTHERAPY IN PETS for more information).

Another medical treatment sometimes discussed is the oral nonsteroidal anti-inflammatory (aspirin-like) drug piroxicam. There is evidence that piroxicam can have an antitumor effect in certain canine cancers other than melanoma and indirect, word of mouth suggestion that it may be effective for some canine melanomas as well, although detailed statistics are lacking.

**FOLLOW-UP**

At various time points during and after treatment, it is important to pursue rechecks for evidence of regrowth or spread to the lymph nodes or lungs. Should these be seen in the future, there may be other types of treatment available. A typical recheck schedule would involve evaluation of the local site, lymph nodes and lungs every 2-3 months for 18 months, then twice yearly thereafter.